RPID NASDAQ

Rapid Micro Biosystems, Inc. operates as a life sciences technology firm, supplying advanced solutions for identifying microbial impurities in the production processes of pharmaceuticals, medical devices, and personal care goods across North America, Europe, and Asia. Central to their offerings is the Growth Direct platform, a comprehensive system comprising the Growth Direct instrument, specialized disposable components, software for seamless integration with laboratory information management systems (LIMS), and extensive customer validation and support services. This innovative platform is designed to automate and modernize traditional, labor-intensive microbial quality control (MQC) testing workflows, which are critical for diverse therapeutic modalities such as biologics, vaccines, cutting-edge cell and gene therapies, and sterile injectable medications. Beyond their core product, the company also delivers essential services, including system installation, verification, expert technical training, and continuous support. Their technologies are widely applied in vital areas like environmental monitoring, water quality testing, bioburden assessment, and final sterility release evaluations. Established in 2006, the company initially traded as Genomic Profiling Systems, Inc., before rebranding to Rapid Micro Biosystems, Inc. in January 2007, and maintains its headquarters in Lowell, Massachusetts.